US central nervous system specialist Axsome Therapeutics (Nasdaq: AXSM) saw its shares rocket more than 32% to $74.84 yesterday, after it announced positive late-stage clinical results with its drug candidate in Alzheimer’s disease agitation.
The company said that AXS-05 (dextromethorphan bupropion), a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) Phase III trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer’s disease, as compared to placebo.
In August this year, AXS-05 was approved in the USA for the treatment of depression under the trade name Auvelity and moving into Alzheimer’s agitation would be an important expansion. Chris Howerton, an analyst at Jefferies, previously predicted the drug could generate as much as $1.8 billion in peak yearly sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze